Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2800-2808

  Kinoshita, Akiyoshi ^a   Onoda, Hiroshi ^a   Takano, Keiko ^a   Imai, Nami ^a   Saeki, Chisato ^a   Fushiya, Nao ^a   Miyakawa, Yoshinari ^a   Nishino, Hirokazu ^a   Tajiri, Hisao ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C reactive protein; Hepatocellular carcinoma; Prognostic marker

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; SORAFENIB;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERODIAGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 84867987446     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0220-1     Document Type: Article

References (28)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7:448-58.
2. Stiff GM, Gomez D, Prasad KR. C-reactive protein in liver cancer surgery. Eur J Surg Oncol. 2008;34:727-9.
3. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197-201.
4. Rashid SA, Quigley JO, Axon ATR, Cooper EH. Plasma protein profiles and prognosis in gastric cancer. Br J Cancer. 1982;45:390-4.
5. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998;176:335-8.
6. McMillan DC, Canna K, McArdlle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215-9.
7. Ueno H, Okada S, Okusaka T, Ikeda M. Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology. 2000;59:296-301.
8. Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdlle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002;87:264-7.
9. Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol. 1999;162:1934-7.
10. Pierce BL, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437-44.
11. Kodama J, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999;82:107-10.
12. Hashimoto K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856-64.
13. Nagaoka S, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007;27:1091-7.
14. Tokushige K, et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45:960-7.
15. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma. Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-22.
16. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
17. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751-5.
18. Kudo M, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-405.
19. Makuuchi M, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37-51.
20. Heikkila K, Eblahim S, Lawlor D. A systematic review of the association between circulating concentrations of C-reactive protein and cancer. J Epidemiol Community Health. 2007;61:824-32.
21. Legouffe E, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leukemia Lymphoma. 1998;31:351-7.
22. Chun JM, et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol. 2011;103:148-51.
23. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250-5.
24. Pawlic TM, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg. 2005;140:450-8.
25. Nathan H, Schulick RD, Choti MA, Pawlic TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805.
26. Sakata H, et al. Prognostic factors for hepatocellular carcinoma presenting with macroscopic portal vein tumor thrombus. Hepatogastroenterology. 2004;51:1575-80.
27. Pinter M, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2011;34:949-59.
28. Huitzil-Melendez FD, et al. Advanced hepatocellular carcinoma: which staging system best predict prognosis? J Clin Oncol. 2010;28:2889-95.